Amgen is only weeks away from an anticipated FDA approval for its PCSK9 cholesterol lowerer. Already approved in Europe, the drug is expected to quickly reap blockbuster sales. The biotech's current portfolio of products, along with cost cuts, have helped set the stage for a big year that could possibly include M&A.
Rehabilitation specialist AlterG has wrapped up $15 million in debt to back its products that include a leg-worn motor assistance device AlterG Bionic Leg as well as a low-gravity treadmill. The financing comes during an ongoing renaissance for novel mobility assistance devices.
Monroeville, PA-based startup Rinovum Women's Health has gained $6 million to back its commercialization efforts for its home-use conception assistance device that was cleared by FDA last fall. That's according to a SEC filing; the financing is an expansion of an infusion of just $700,000 it reported earlier this year.
Healthcare was one of the strongest segments at German conglomerate Siemens last quarter, both in terms of sales growth and profitability. That could help insulate this business, comprised mostly of imaging and diagnostics, from an ongoing restructuring that aims to trim employees and costs from its worst performing businesses.
Veterinary diagnostics maker IDEXX reported on Thursday that its revenues for the second quarter grew 6% year over year to $413 million, as placements of its blood analysis systems hit a record of 900 units for the period. Placements of its Catalyst One next-generation chemistry analyzer skyrocketed 44% to an all-time record of 1,100 units, the company said in a press release announcing the results.
Distributor Henry Schein, which is undergoing a major expansion of its animal health business, reported that earnings in the second quarter grew 8% year over year to $123.2 million or $1.46 per diluted share, on sales that rose a half-percent to $2.6 billion.
Zimmer Biomet officials spent the newly combined company's Q2 2015 earnings call describing the company's sales and marketing strategy as it seeks to ramp up growth in 2016 following ongoing integration efforts. The company reiterated its pledge to retain sales reps rather than cut them in an effort to achieve synergies.
Moving quickly to show investors a change of direction is ahead, Novogen acting Chief Executive Iain Ross announced a company-wide review of its preclinical programs less than a week after the abrupt departure of his predecessor, Graham Kelly.
AstraZeneca's closely watched blood thinner Brilinta came through for the drugmaker in the second quarter, as did its diabetes franchise, allowing the British company to pull off a 2% rise in sales (at constant exchange rates) to $6.3 billion and core operating profit of $1.8 billion, or $1.21 a share.
Charles River Laboratories saw its sales dip in the second quarter, but the early-stage specialist is counting on some recent acquisitions to spur growth for the full year.